<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01507285</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-1189</org_study_id>
    <nct_id>NCT01507285</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Dose-escalation, Parallel-group, Single and Multiple Dosing Trial of NN90-1170 in Healthy Volunteers and Patients With Type 2 Diabetes to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to assess the safety and
      tolerability (maximum tolerated dose) after single and multiple doses of NNC 90-1170
      (liraglutide) in healthy volunteers and in subjects with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 1999</start_date>
  <completion_date type="Actual">November 1999</completion_date>
  <primary_completion_date type="Actual">November 1999</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the Curve</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax, maximum concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax, time to maximum concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½, terminal half-life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NNC 90-1170</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only</description>
    <arm_group_label>NNC 90-1170</arm_group_label>
    <other_name>NNC 90-1170</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Initial single dose followed by subsequent multiple s.c. (under the skin) doses</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HEALTHY VOLUNTEERS

          -  Healthy subjects aged 18-45 years inclusive

          -  Healthy subjects are defined as individuals free from significant cardiac, pulmonary,
             gastrointestinal, hepatic, renal, haematological, neurological and psychiatric disease
             as determined by history, physical examination and clinical laboratory test results

          -  Women who are not of childbearing potential

          -  Signed and dated written informed consent obtained

          -  Body mass index (BMI) within the range 19-30 kg/m^2, inclusive

          -  SUBJECTS WITH DIABETES

          -  Subjects aged 40-70 years inclusive

          -  Subjects diagnosed with type-2 diabetes and a duration of diabetes of more than 12
             months

          -  Women who are not of childbearing potential

          -  Signed and dated written informed consent obtained

          -  Fasting C-peptide at least 0.3 nmol/l and blood glucose at least 7 mmol/l

          -  Subjects currently on diet and/or OHA (oral hypoglycemic agents) for at least six
             months

          -  Body mass index (BMI) below 35 kg/m^2

          -  HbA1c (glycosylated haemoglobin) below 11%

          -  Stable on current medication for at least 3 weeks prior to dosing in this study

        Exclusion Criteria:

          -  HEALTHY VOLUNTEERS

          -  Clinically relevant abnormal history or physical findings (e.g. cancer) at the
             screening assessment, which could interfere with the objectives of the study or the
             safety of the subject's participation

          -  Clinically relevant abnormalities of laboratory values or ECG at the screening
             evaluation

          -  Presence of acute or chronic illness sufficient to invalidate the subject's
             participation in the study or to make it unnecessarily hazardous

          -  Blood pressure and heart rate in seated position at the screening examination outside
             the ranges 90-150 mmHg systolic, 40-90 mmHg diastolic: heart rate 40-100 beats/min

          -  History of drug or alcohol abuse (alcohol abuse is defined as intake of more than 28
             units weekly in men and more than 21 units weekly in women)

          -  Alcohol intake within 48 hours prior to visit

          -  Evidence of drug abuse on urine testing at study entry

          -  The subject smokes 10 cigarettes or more, or the equivalent, per day and is unable to
             refrain from smoking during 3 days prior to the first dosing day and during the
             confinement period

          -  Hepatitis B surface antigen (HBsAg), Hepatitis C antibodies or HIV (human
             immunodeficiency virus) antibodies

          -  History of significant drug allergy or drug hypersensitivity

          -  SUBJECTS WITH DIABETES

          -  Use of any drug (except for oral hypoglycaemic agents (OHAs)) which in the
             Investigator's opinion could interfere with the blood glucose level (e.g. insulin,
             systemic corticosteroids, thiazides)

          -  Recurrent severe hypoglycaemia as judged by the Investigator

          -  Clinically relevant abnormal history or physical findings (e.g. cancer) at the
             screening assessment, which could interfere with the objectives of the study or the
             safety of the subject's participation

          -  Clinically relevant abnormalities of laboratory values or ECG at the screening
             evaluation

          -  Presence of acute or chronic illness sufficient to invalidate the subject's
             participation in the study or to make it unnecessarily hazardous

          -  Blood pressure and heart rate in seated position at the screening examination outside
             the ranges 110-160 mmHg systolic, 60-90 mmHg diastolic: heart rate 40-100 beats/min

          -  History of drug or alcohol abuse (alcohol abuse is defined as intake of more than 28
             units weekly in men and more than 21 units weekly in women)

          -  Alcohol intake within 48 hours of visit

          -  Evidence of drug abuse on urine testing at study entry

          -  The subject smokes 10 cigarettes or more, or the equivalent, per day and is unable to
             refrain from smoking during 3 days prior to the first dosing day and during the
             confinement period

          -  Hepatitis B surface antigen (HBsAg), Hepatitis C antibodies

          -  History of significant drug allergy or drug hypersensitivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002 Feb;45(2):195-202.</citation>
    <PMID>11935150</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2012</study_first_submitted>
  <study_first_submitted_qc>January 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2012</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

